Medicus Pharma Ltd.宣布,阿联酋卫生部门已正式批准其开展Teverelix的Precision-E2 2a期临床研究。这一授权标志着该药物研发进程中的重要里程碑。获批的临床试验将聚焦于评估Teverelix的疗效与安全性,为后续研究奠定基础。
Medicus Pharma Ltd.宣布,阿联酋卫生部门已正式批准其开展Teverelix的Precision-E2 2a期临床研究。这一授权标志着该药物研发进程中的重要里程碑。获批的临床试验将聚焦于评估Teverelix的疗效与安全性,为后续研究奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.